Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 09, 2020 | June 12, 2020 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 16, 2023 | June 21, 2023 |
| Guardant Health, Inc.GH · Entity 3238 | Director | September 16, 2026 | September 17, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 09, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2030-06-09 | Direct | 15,000 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,202 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 38,202 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 781,797 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 781,797 F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Gritstone bio, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-15 | Direct | 51,800 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 51,800 · Balance 51,800 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
Guardant Health, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,906 |
Ending reported balance
After 2026-09-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,103 · Balance 13,477 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-09-16 · Sale · Disposed 3,300 · Balance 10,177 F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-09-16 · Sale · Disposed 1,300 · Balance 8,877 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-09-16 · Sale · Disposed 971 · Balance 7,906 F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 4, 2025 23:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000048 · wk-form4_1741129549.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,469 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000048 · wk-form4_1741129549.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000032 · wk-form4_1738707094.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,623 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award vests substantially in equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000032 · wk-form4_1738707094.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 01:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,339 | $20.81 | $69,484.59 |
DisclosureSEC source: 0001714899-25-000048 · wk-form4_1736385830.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,757 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · balance_after: Includes 5,967 Unvested RSUs. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:52 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000002 · wk-form4_1735854742.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,777 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:52 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000002 · wk-form4_1735854742.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 30,000 | $20.25 | $607,500.00 |
DisclosureSEC source: 0001714899-25-000002 · wk-form4_1735938858.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,096 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.10 to $20.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects an allocation of 30,000 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person. F4 · balance_after: Includes 13,467 Unvested RSUs. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 00:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000289 · wk-form4_1733185194.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,932 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 00:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000289 · wk-form4_1733185194.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 22:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000253 · wk-form4_1730759290.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,086 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 22:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000253 · wk-form4_1730759290.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000228 · wk-form4_1727819887.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,240 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000228 · wk-form4_1727819887.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 30,000 | $29.03 | $870,900.00 |
DisclosureSEC source: 0001714899-24-000200 · wk-form4_1727901447.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,096 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.50 to $29.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects an allocation of 26,419 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person. F4 · balance_after: Includes 13,467 Unvested RSUs. Read SEC document |
| August 31, 2024 Filed Sep 3, 2024 20:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000196 · wk-form4_1725396217.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,394 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 31, 2024 Filed Sep 3, 2024 20:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000196 · wk-form4_1725396217.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:15 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,727 | $23.79 | $41,085.33 |
DisclosureSEC source: 0001714899-24-000196 · wk-form4_1724357741.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,677 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.75 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 13,467 Unvested RSUs. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 22:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000184 · wk-form4_1722552399.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,549 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 22:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000184 · wk-form4_1722552399.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 4, 2024 01:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 100 | $22.80 | $2,280.00 |
DisclosureSEC source: 0001714899-24-000156 · wk-form4_1720055619.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,404 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023. F1 · balance_after: Includes 18,467 unvested RSUs. Read SEC document |
| July 01, 2024 Filed Jul 4, 2024 01:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 29,900 | $22.12 | $661,388.00 |
DisclosureSEC source: 0001714899-24-000156 · wk-form4_1720055619.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,504 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $21.80 to $22.78 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 18,467 unvested RSUs. F4 · balance_after: Reflects an allocation of 11,784 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:49 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000160 · wk-form4_1719953336.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,703 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:49 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000160 · wk-form4_1719953336.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:57 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 53,528 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001746473-24-000090 · wk-form4_1718668632.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,528 Underlying: Common Stock · 53,528 shares Expires 2034-06-13 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of June 13, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 13, 2024 Filed Jul 4, 2024 01:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 688 | $21.79 | $14,991.52 |
DisclosureSEC source: 0001714899-24-000156 · wk-form4_1720055619.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,620 F1 · balance_after: Includes 18,467 unvested RSUs. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 00:56 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 6,674 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000138 · wk-form4_1718326588.xml · derivative · entry 4 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,674 Underlying: Common Stock · 6,674 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 00:56 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantStock Option (Right to Buy) · Derivative | 10,703 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001576280-24-000138 · wk-form4_1718326588.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,703 Underlying: Common Stock · 10,703 shares Expires 2034-06-12 F3 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 00:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 5,592 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000138 · wk-form4_1718326588.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 00:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 5,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000138 · wk-form4_1718326588.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000122 · wk-form4_1717453190.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,857 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000122 · wk-form4_1717453190.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,901 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001714899-24-000142 · wk-form4_1717540391.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000142 · wk-form4_1717540391.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,308 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 18,467 unvested RSUs. Read SEC document |
| April 30, 2024 Filed May 2, 2024 21:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000096 · wk-form4_1714683784.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,012 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 30, 2024 Filed May 2, 2024 21:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000096 · wk-form4_1714683784.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 92,500 | $20.50 | $1,896,250.00 |
DisclosureSEC source: 0001714899-24-000098 · wk-form4_1712095651.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,341 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.06 to $20.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 16,716 unvested RSUs. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 21:25 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000076 · wk-form4_1712006700.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,166 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 21:25 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000076 · wk-form4_1712006700.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000047 · wk-form4_1709330881.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,320 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000047 · wk-form4_1709330881.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 02:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,750 | $17.29 | $47,547.50 |
DisclosureSEC source: 0001714899-24-000062 · wk-form4_1708049752.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,841 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.07 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 16,716 RSUs. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 22:38 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000028 · wk-form4_1706827123.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,474 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 22:38 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000028 · wk-form4_1706827123.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,208 | $19.43 | $62,331.44 |
DisclosureSEC source: 0001714899-24-000037 · wk-form4_1704846873.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,591 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.37 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 24,002 RSUs. Read SEC document |
| December 31, 2023 Filed Jan 2, 2024 23:06 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000002 · wk-form4_1704236774.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,629 Underlying: COMMON STOCK · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 31, 2023 Filed Jan 2, 2024 23:06 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000002 · wk-form4_1704236774.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 23:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000195 · wk-form4_1701732132.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,783 Underlying: COMMON STOCK · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 23:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000195 · wk-form4_1701732132.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000181 · wk-form4_1698883625.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,937 Underlying: COMMON STOCK · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests as to 25% of the shares subject to such award on June 30, 2023, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.